Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study)

NCT07001280 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT07001280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07001280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study)
Lead sponsor
CSL Behring
Phase
Observational
Overall status
Recruiting
Start date
July 21, 2025
Completion date
August 31, 2030
Enrollment
200 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedemas